Fragmento

Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality worldwide despite being largely preventable through effective screening and early intervention. According to recent global epidemiological estimates, CRC is currently the third most commonly diagnosed malignancy and the second leading cause of cancer death globally, reflecting persistent deficiencies in population-based screening programs and inequities in healthcare access. In this context, the fecal immunochemical test (FIT) has emerged as one of the most transformative noninvasive strategies for the early detection of colorectal neoplasia.

The FIT represents a major advancement over traditional guaiac-based fecal occult blood testing (gFOBT). Unlike gFOBT, FIT specifically detects human globin through immunochemical methods, thereby improving analytical specificity for lower gastrointestinal bleeding and eliminating dietary restrictions that historically reduced adherence to screening programs. The increased sensitivity and patient acceptability associated with FIT have significantly enhanced participation rates in organized CRC screening initiatives.

Palabras clave:

2026-06-18   |   1 visitas   |   Evalua este artículo 0 valoraciones

Vol. 15 Núm.2. Abril-Junio 2026 Pags. 45-46 Rev Mex Cirug Apar Diges 2026; 15(2)